Why is gout so poorly managed?

Annals of the Rheumatic Diseases

Volumn 66, Issue 10, 2007, Pages 1269-1270

  Pascual, Eliseo ^a   Sivera, Francisco ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

URATE; URIC ACID;

EDITORIAL; GENERAL PRACTITIONER; GOUT; HEALTH CARE QUALITY; HYPOURICEMIA; METABOLIC SYNDROME X; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; UNITED KINGDOM;

ARTHRITIS, RHEUMATOID; ATTITUDE OF HEALTH PERSONNEL; FAMILY PRACTICE; GOUT; HUMANS; JOINTS; URIC ACID;

EID: 34848901921     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.078469     Document Type: Editorial

References (39)

1. Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007;19:122-7.
2. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961;54:452-60.
3. Pascual E, Batlle-Gualda E, Martínez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999;131:756-9.
4. Sivera F, Aragón R, Pascual E. First metatarsophalangeal joint aspiration using a 29-gauge needle. Ann Rheum Dis 2007M; doi:10.1136/ard.2007.073460.
5. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR Jr. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.
6. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; doi:10.1136/ard.2006.060368.
7. van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993;20:1383-5.
8. Bull PW, Scott JT, Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989;16:1246-8.
9. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout - Part I Diagnosis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
10. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, et al. EULAR Evidence based recommendations for gout - part ii management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;25:1301-11.
11. Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, Bilker WB, Saag KG. Quality of care indicators for gout management. Artritis Rheum 2004;50:937-43.
12. Schumacher HR Jr, Edwards LN, Pérez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H. OMERACT 7 Special Interest Group: Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2453-5.
13. Lumbreras B, Pascual E, Frasquet J, González-Salinas J, Rodríguez E, Hernández-Aguado I. Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann Rheum Dis 2005;64:612-15.
14. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu T-F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
15. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81.
16. Annemans L, Spaepen E, Nash C, Bonnemaire M, Gilbert T, Malier V. Medical management of chronic gout in the UK and Germany [abstract]. Ann Rheum Dis 2006;65(Suppl 2):430.
17. Pérez-Ruiz F. Treatment of gout before rheumatology consultation is far from that recommended [abstract]. Ann Rheum Dis 2006;65(Suppl 2):436.
18. Mikuls TR, Curtis JR, Allison JJ, Hicks RW, Saag KG. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 2006;33:562-6.
19. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
20. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33:104-9.
21. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary care population with the EULAR gout recommendations. Ann Rheum Dis 2007; doi:10.1136/ard.2007.070755.
22. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal adherence to quality indicators for the management of gout and asymptomatic hyperuricemia: results form the UK General Practice Research Database (GPRD). Rheumatology 2005;44:1038-42.
23. Pal B, Foxall M, Dysart T, Carey F, Whittaker M. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000;19:21-5.
24. Schlesinger N, Moore DF, Sun JD, Schumacher HR Jr. A survey of current evaluation and treatment of gout. J Rheumatol 2006;33:2050-2.
25. Fang W, Zeng X, Li M, Chen LX, Schumacher HR Jr, Zhang F. The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol 2006;33:2041-9.
26. Vazquez-Mellado J, Espinoza J, Hernandez-Garduno A, Lino L, Burgos-Vargas R. Diagnosis and treatment of gout in Mexico City. Results from a physician survey (in Spanish). Rev Invest Clin 2003;55:621-8.
27. Sueter LG, Fraenkel L, Holmboe ES. What factors account for referral delays for patients with suspected rheumatoid arthritis? Arthritis Rheum 2006;55:300-5.
28. Herman CJ, Allen P, Hunt WC, Prasad A, Brady TJ. Use of complementary therapies among primary care clinic patients with arthritis. Prev Chronic Dis 2004;1:A12.
29. Bannwarth B, Logeart I, Vergult G. Prescribing patterns of rofecoxib in the primary care setting: results of a French survey. Rev Med Interne 2004;25:710-14.
30. Mitchell E, McConnahie A, Sullivan F. Consultation computer use to improve management of chronic disease in general practice : a before and after study. Inform Prim Care 2003;11:61-8.
31. Solomon DH, Warsi A, Brown-Stevenson T, Farell M, Gauthier S, Mikels D, et al. Does self-management education benefit all population with rheumatoid arthritis? J Rheumatol 2002;29:362-8.
32. Spencer-Green G, Spencer-Green E. Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: how physicians manage treatment failures. J Rheumatol 1998;25:2088-93.
33. Mittendorf T, Merkesdal S, Zeidler H, Graf con der Schukenburg JM, Ruof J. Costs of ambulatory care for RA patients in Germany. Med Klin (Munich) 2005;100:255-61.
34. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005;23:80-4.
35. Powell JE, Langley C, Kirwan J, Gubia D, Medel D, Pollck J, et al. Welfare rights services for people disabled with arthritis integrated in primary care and hospital settings: set-up, costs, and monetary benefits. Rheumatology 2004;43:1167-72.
36. Charalambous C, Paschalides C, Sadiq S, Tryfonides M, Hirst P, Paul AS. Weight bearing following intra-articular steroid injection of the knee: survey of current practice and review of the available evidence. Rheumatol Int 2002;22:185-7.
37. Gabriel SE, Wagner JL, Zinsmeiter AR, Scot CG, Luthra HS. Is rheumatoid arthritis care more costly when provided by rheumatologists compared with generalists? Arthritis Rheum 2001;44:1504-14.
38. Hulsemann JL. Cooperation between the family physician, rheumatologist, hospital and rehabilitation clinic. Contribution of regional cooperative rheumatic disease centres for total quality management. Z Rheumatol 1998;57:424-7.
39. Criswell LA, Duch CI, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologist and nonrheumatologists. J Rheumatol 1997;24:2283- 90.